Cross Country Healthcare (NASDAQ:CCRN - Get Rating) had its target price increased by investment analysts at Credit Suisse Group to $31.00 in a report issued on Thursday, Stock Target Advisor reports. Credit Suisse Group's price target points to a potential downside of 11.96% from the stock's current price.
A number of other brokerages have also issued reports on CCRN. Truist Financial lowered shares of Cross Country Healthcare from a "buy" rating to a "hold" rating and set a $36.00 price objective for the company. in a report on Wednesday, October 5th. They noted that the move was a valuation call. StockNews.com initiated coverage on shares of Cross Country Healthcare in a report on Wednesday, October 12th. They issued a "hold" rating for the company. Benchmark raised their price objective on shares of Cross Country Healthcare from $37.00 to $42.00 and gave the company a "buy" rating in a report on Thursday, September 15th. Finally, Barrington Research raised their price target on shares of Cross Country Healthcare from $41.00 to $45.00 and gave the stock an "outperform" rating in a report on Monday, November 7th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Cross Country Healthcare has an average rating of "Moderate Buy" and an average price target of $36.20.
Cross Country Healthcare Price Performance
Shares of CCRN traded down $0.78 during mid-day trading on Thursday, reaching $35.21. The company had a trading volume of 382,657 shares, compared to its average volume of 877,285. The company's 50 day simple moving average is $32.75 and its 200 day simple moving average is $25.77. Cross Country Healthcare has a 1-year low of $15.26 and a 1-year high of $40.12. The company has a debt-to-equity ratio of 0.31, a quick ratio of 2.38 and a current ratio of 2.38. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of 5.84, a P/E/G ratio of 1.19 and a beta of 1.00.
In other news, General Counsel Susan E. Ball sold 44,357 shares of Cross Country Healthcare stock in a transaction on Monday, September 19th. The shares were sold at an average price of $28.99, for a total value of $1,285,909.43. Following the completion of the sale, the general counsel now owns 170,797 shares in the company, valued at approximately $4,951,405.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Cross Country Healthcare news, Director W Larry Cash purchased 1,500 shares of Cross Country Healthcare stock in a transaction that occurred on Tuesday, August 30th. The stock was acquired at an average price of $25.60 per share, with a total value of $38,400.00. Following the transaction, the director now owns 177,899 shares in the company, valued at approximately $4,554,214.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Susan E. Ball sold 44,357 shares of Cross Country Healthcare stock in a transaction on Monday, September 19th. The stock was sold at an average price of $28.99, for a total transaction of $1,285,909.43. Following the transaction, the general counsel now directly owns 170,797 shares in the company, valued at $4,951,405.03. The disclosure for this sale can be found here. Insiders sold 114,256 shares of company stock worth $3,404,694 in the last quarter. 5.00% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Cross Country Healthcare
A number of hedge funds have recently made changes to their positions in the business. US Bancorp DE bought a new stake in Cross Country Healthcare during the 1st quarter valued at $27,000. Point72 Hong Kong Ltd bought a new position in shares of Cross Country Healthcare during the first quarter valued at about $35,000. Gladius Capital Management LP bought a new position in shares of Cross Country Healthcare during the second quarter valued at about $60,000. KBC Group NV bought a new position in Cross Country Healthcare in the second quarter worth about $65,000. Finally, Captrust Financial Advisors increased its stake in shares of Cross Country Healthcare by 26.4% during the first quarter. Captrust Financial Advisors now owns 3,074 shares of the business services provider's stock valued at $67,000 after purchasing an additional 642 shares in the last quarter. 95.25% of the stock is currently owned by institutional investors.
About Cross Country Healthcare
Cross Country Healthcare, Inc provides talent management and other consultative services for healthcare clients in the United States. The company operates in two segments, Nurse and Allied Staffing and Physician Staffing. The Nurse and Allied Staffing segment offers traditional staffing, including temporary and permanent placement of travel nurses and allied professionals, local nurses, and allied staffing; staffing solutions for registered nurses, licensed practical nurses, certified nurse assistants, practitioners, pharmacists, and other allied professionals on per diem and short-term assignments; and clinical and non-clinical professionals on long-term contract assignments, as well as workforce solutions, including MSP, RPO, and consulting services.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to email@example.com.
Before you consider Cross Country Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cross Country Healthcare wasn't on the list.
While Cross Country Healthcare currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here